Compare LAB & JRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LAB | JRI |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Finance Companies |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 326.2M | 356.8M |
| IPO Year | 2008 | N/A |
| Metric | LAB | JRI |
|---|---|---|
| Price | $0.69 | $11.70 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.35 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 140.3K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.38% |
| EPS Growth | ★ 61.54 | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $101,937,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.63 | N/A |
| P/E Ratio | $2.65 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.63 | $11.67 |
| 52 Week High | $1.72 | $14.37 |
| Indicator | LAB | JRI |
|---|---|---|
| Relative Strength Index (RSI) | 47.52 | 28.59 |
| Support Level | $0.63 | $11.67 |
| Resistance Level | $1.02 | $13.11 |
| Average True Range (ATR) | 0.03 | 0.15 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 61.73 | 11.76 |
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
Nuveen Real Asset Income and Growth Fund is a closed-end fund. Its objective is to provide a high level of current income and long-term capital appreciation. The fund invests a majority of its managed assets in equity and debt securities issued by real asset related companies located anywhere in the world. Its plan involves investments in five security types, infrastructure common stock, REIT preferred stock and debt securities. Real asset-related companies include those engaged in owning, operating, or developing infrastructure projects, facilities, and services, as well as REITs.